Hospital-Acquired Infections Market Size will exponentially grow from 2022 to 2028 owing to the booming geriatric population coupled with the pervasiveness of poor hygiene standards and healthcare administrations. Excessive crowding and humidity as well as the lack of awareness are factors adding to the infected material and bacterial load across hospitals. The rising burden of chronic diseases worldwide and the surge in several surgical procedures will lead to market progression.
Hospital-acquired infections, including bloodstream infections, ventilator-associated pneumonia, surgical site infections, and urinary tract infections, are primarily caused by viral, bacterial, as well as fungal pathogens. The increasing number of hospital admissions is a major contributor to the market expansion.
With respect to infection type, the market share from the urinary tract infection (UTI) segment is set to expand with the growing number of hospital admissions that require urinary catheters. As per the CDC (Centers for Disease Control and Prevention), the total count of catheter-associated urinary tract infections in the U.S. exceeded 19,738 in 2020. The rising burden of these infections has infused a positive scenario for the overall market growth.
Based on distribution channels, the hospital-acquired infections market size from retail pharmacies will commendably rise with the easy availability of medicines in these facilities. Apart from the simplicity of access offered by them, retail pharmacies assist with the transition period and are mindful of the patient’s needs, whilst following through with every step of the way. The growing count of retail pharmacies across the globe is another significant trend favoring the market growth. According to the National Community Pharmacists Association (NCPA), there are currently over 22,500 independent pharmacies in the U.S, which dispense close to half of the country’s retail prescription medicines.
The hospital-acquired infections market in the Asia Pacific is slated to witness lucrative growth owing to growing awareness and the rise in funds from the government & non-government sectors. The growing burden of chronic diseases along with the higher disposable incomes have paved the path for the increasing number of hospital admissions.
The rising adoption of sterilization & disinfection equipment has resulted in higher technological enhancements in medical device manufacturing. The expanding R&D sector, the presence of a vast population base, and the growing instances of hospital-acquired infections, notably in the emerging economies are some of the important factors adding to the regional market growth.
AstraZeneca, Cepheid (Danaher Corporation), F. Hoffmann-La Roche, Johnson & Johnson, Daiichi Sankyo, Merck, Bayer, Cipla, Eli Lilly, and Company, GlaxoSmithKline, Bristol-Myers Squibb, Abbott, and Pfizer are some companies operating in the hospital-acquired infections market.
These frontrunners are actively adopting strategic measures, including acquisitions, mergers, and partnerships, in a bid to reinforce their global footprint and are also constantly turning to new product launches and drug approvals, to cater to the growing requirements.
For instance, in June 2021, STERIS plc acquired Cantel Medical, a well-known infection prevention product, and services provider. It helped the firm to complement and extend its global reach, product and service offerings, as well as customers.
In another instance, in October 2019, Cipla Limited purchased Elores, a patented anti-infective product, from Venus Remedies Limited for the Indian market to further reinforce its presence in the branded Indian critical care space and in a bid to contribute to its fight against AMR (Anti-Microbial Resistance).
The COVID-19 crisis prompted massive roadblocks for most businesses and substantially hampered the global economy. It however opened major growth avenues for the hospital-acquired infection industry considering the rising burden of the infection in the affected patients. The growing efforts that were undertaken by market players also influenced the industry growth. For instance, in March 2021, Eli Lilly and Company, GlaxoSmithKline plc, along with Vir Biotechnology, Inc. announced topline data from expanded Phase 2 BLAZE-4 trial that studies the low-risk adult patients having mild to moderate infection.
Market, By Infection Type
Market, By Treatment
Market, By Distribution Channel
The above information is provided for the following regions and countries: